Medix Biochemica

In 1985, inspired by a Nobel Prize-winning discovery in antibody production, Medix Biochemica was founded in Finland. A key figure in its early days was Finnish scientist Jim Schröder, who, after working at Stanford University, brought his expertise back to the company and served as a long-standing board member. The company's focus was clear: to produce high-quality monoclonal antibodies and other raw materials for the in vitro diagnostics (IVD) industry. For years, the company grew steadily, establishing itself as a critical supplier for diagnostic test manufacturers worldwide. A significant turning point came in 2018 when the Finnish investment company DevCo Partners acquired a majority stake, with the goal of accelerating growth and transforming Medix Biochemica into a global leader. The Minerva Foundation, a previous majority shareholder, continued as a significant owner. This new partnership kicked off a period of rapid expansion. Medix Biochemica embarked on a series of strategic acquisitions to broaden its portfolio and strengthen its global presence. Between 2019 and early 2025, the company acquired numerous businesses across the US and Europe, including Lee Biosolutions, EastCoast Bio, Diaclone, ViroStat, and CANDOR Bioscience. This strategy expanded its offerings from antibodies to molecular diagnostics, enzymes, and stabilizers. Through this journey of organic growth and strategic acquisitions, Medix Biochemica has become a key partner for the IVD industry, supplying essential components for countless diagnostic tests.